CAPSOVISION INC
CVNASDAQTrading Snapshot
- Day Range
- $7.07 – $7.24
- 52-Week Range
- $4.50 – $15.37
- Volume (shares)
- 34,606.897
- Avg Volume (shares)
- —
- Shares Outstanding
- 53.2M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $4M
- P/E Ratio
- —
- P/S Ratio
- 26.4x
- EPS (TTM)
- $-0.63
- Dividend Yield
- —
- Dilution (1yr)
- +1.1%
CAPSOVISION INC
CV
StockOtter · stockotter.spaceAbout CAPSOVISION INC
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
CapsoVision Maps AI Capsule Push Into Colon, Pancreatic Cancer Screening
CapsoVision NASDAQ: CV outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificial
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
SKYRIZIÂ (risankizumab) and RINVOQÂ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2
CapsoVision to Present at the 20th Annual LD Micro Main Event
SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced th
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
New SKYRIZIÂ (risankizumab-rzaa) and RINVOQÂ (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel DiseasePR NewswireNOR
Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)
CapsoVision (NASDAQ: CV - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the streng
CapsoVision (NASDAQ:CV) and NeuroPace (NASDAQ:NPCE) Critical Contrast
NeuroPace (NASDAQ: NPCE - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the stren